Tianjin Medical University Cancer Institute and Hospital: Adenocarcinoma trials

The registry lists 11 Adenocarcinoma studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 2 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07689292Phase 2
• Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction CancerRecruitingNCT06496789Phase 2
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
• Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingNCT06454435Phase 2
• A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal AdenocarcinomaRecruitingNCT05997147
• Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric CancerNot yet recruitingNCT05974059Phase 2
• Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Not yet recruitingNCT04965831Phase 2
• Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT04908566Phase 2
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ AdenocarcinomaStatus unknownNCT04813523Phase 2
• Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT04631757Phase 2